Gonorrhea Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
Gonorrhea is an infection caused by a sexually transmitted bacterium that infects both males and females. The primary factors such as the rising prevalence of gonorrhea, implementation of national screening programs and growing public awareness are propelling the growth of the gonorrhea therapeutics market. According to the Centers for Disease Control and Prevention (CDC), around 700,000 new cases of gonorrhea are detected each year. In 2019, the National Institute of Allergy and Infectious Diseases (NIAID) has granted USD 41.6 million over five years to support collaborative, multidisciplinary research on the bacteria that cause syphilis, gonorrhea, and chlamydia. Thus, with the growing prevalence of STDs increases patient awareness through national campaigns and growing government initiatives are anticipated to drive market growth.
However, stringent regulatory scenarios and social stigma associated with patients visiting STD clinics are expected to restrain the growth of the global market in the forecast period.
Key Market TrendsDual Therapy Segment is Expected to Register Good Growth Over the Forecast PeriodBy Treatment, the market has been segmented into monotherapy and dual therapy. Gonorrhea, caused by Neisseria gonorrhoeae, is the second most common bacterial STI and results in substantial morbidity. The dual therapy segment is estimated to dominate the global market, and this trend is expected to continue over the forecast period. Dual therapy with ceftriaxone and azithromycin is recommended as the first-line regimen for the treatment of gonorrhea. WHO recommends dual therapy over monotherapy for people with symptomatic and asymptomatic gonorrhea. Also, monotherapy is no longer a viable option in many settings worldwide. In addition, growing public awareness and a large patient pool also contribute to the growth of the gonorrhea therapeutics market.
North America is Estimated to Lead the Gonorrhea Therapeutics MarketNorth America is expected to lead the market, owing to high standards of healthcare infrastructure and easy availability of sophisticated technology in this region. As per CDC estimates, in 2018 around 583,405 cases of gonorrhea were reported in the United States. However, Europe and the Asia Pacific are followed next after North America owing to the increasing incidence of gonococcal infection, and the rise in collaboration of domestic and international companies in these regions. For instance, In 2019, Binx health announced that its proprietary Chlamydia and Gonorrhea (CT/NG) test has received European CE Mark approval, which is expected to drive the gonorrhea therapeutics market in the forecast period.
Competitive LandscapeThe market for gonorrhea therapeutics is consolidated in terms of competition with a presence of few major pharmaceutical companies. Some of the major players in the gonorrhea therapeutics market includes Allergan, Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Lupin Pharmaceuticals, Pfizer Inc, Teligent, Inc., among others.
Additional Benefits:Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook